![]() ![]() However, while patients who take these drugs have a reduced risk of suffering a stroke or blood clot, they are at risk of suffering from uncontrollable bleeding. The newer generation of blood thinners, Johnson & Johnson's Rivaroxaban and Pfizer's Apixaban, are safer and more effective than the older generation of anticoagulants. With Andexxa being the only reversal agent of its kind, it's easy to see why some investors consider the drug to be the home run that Portola's been looking for. Meant to act as a reversal agent for patients taking anticoagulants - specifically Rivaroxaban and Apixaban - Andexxa could prove to be a lifesaver for patients who suffer side effects of excessive, uncontrollable bleeding caused by the aforementioned drugs. A potential breakthrough in Andexxa?Īndexxa is Portola's top drug candidate at the moment.
0 Comments
Leave a Reply. |